Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

BACKGROUND: Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI therapy in patients with both cancer and chronic viral infections is not well esta...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Shah, Neil J., Al-Shbool, Ghassan, Blackburn, Matthew, Cook, Michael, Belouali, Anas, Liu, Stephen V., Madhavan, Subha, He, Aiwu Ruth, Atkins, Michael B., Gibney, Geoffrey T., Kim, Chul
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6918622/
https://ncbi.nlm.nih.gov/pubmed/31847881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0771-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires